BioStem Technologies Files S-1 for U.S. IPO
BioStem Technologies, Inc. filed an S-1 registration statement with the SEC on October 2, 2026, initiating its IPO process targeting NASDAQ or NYSE listing. The filing does not disclose expected offering size or underwriters, but marks the formal commencement of its U.S. public listing journey.
51CFO view：For pre-IPO companies, the S-1 requires CFOs to demonstrate direct SEC reporting experience and SOX 404 internal control implementation history—especially critical for biotech firms needing ASC 730-compliant R&D capitalization policies validated by auditors.
BioStem Technologies, Inc. filed an S-1 registration statement with the SEC on October 2, 2026, initiating its IPO process targeting NASDAQ or NYSE listing. The filing does not disclose expected offering size or underwriters, but marks the formal commencement of its U.S. public listing journey.
Source：SEC EDGAR · S-1 招股书备案